HOPLive24-MDS
Among the major dilemmas persisting in CAR-T therapy use is how to balance malignancy risks.
Dr. Shammo gives her impressions of how growing incorporation of MDS molecular data is changing disease management.
The expert panel discusses current issues in the use of ESAs within MDS management.
Advertisement
In a roundtable discussion, an expert panel discussed how approval of luspatercept has affected frontline MDS treatment.
Amer Zeidan, MBBS, discusses the unanswered questions in research related to myelodysplastic syndromes.
The expert panel describes how having two separate classification systems for MDS affects their clinical practices.
Advertisement
The expert panel discusses how to explain to patients the range of MDS severities and approach lower-risk disease.
The expert panel discusses molecular testing's current place in MDS evaluation and treatment decisions.
In a roundtable discussion, an expert panel describes recent trends in the classification and prognosis of MDS in the clinic.
The panel mainly focused on how to define and classify MDS and CHIP, as well as how to treat low- and high-risk MDS.
Dr. Zeidan will be participating in the myelodysplastic syndromes panel on the second day of the event
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.